Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The prevalence of intolerance varies widely. Stopping statin therapy is associated with worse outcomes in patients with cardiovascular disease. Despite extensive studies, the benefits and risks of statins continue to be debated by clinicians and the lay public. We searched the PubMed, Medline, and Cochrane Central Register of Controlled Trials (CENTRAL) databases for all randomized controlled trials of statins compared with placebo. Studies were included if they had ≥1,000 participants, had patients who were followed up for ≥1 year, and reported rates of drug discontinuation. Studies were pooled as per the random effects model. A total of 22 studies (statins = 66,024, placebo = 63,656) met the inclusion criteria. The pooled analysis showed that, over a mean follow-up of 4.1 years, the rates of discontinuation were 13.3% (8,872 patients) for statin-treated patients and 13.9% (8,898 patients) for placebo-treated patients. The random effects model showed no significant difference between the placebo and statin arms (odds ratio [OR] = 0.99, 95% confidence interval [CI] = 0.93 to 1.06). The results were similar for both primary prevention (OR = 0.98, 95% CI = 0.92 to 1.05, p = 0.39) and secondary prevention (OR = 0.92, 95% CI = 0.83 to 1.05, p = 0.43) studies. The pooled analysis suggested that the rates of myopathy were also similar between the statins and placebos (OR = 1.2, 95% CI = 0.88 to 1.62, p = 0.25). In conclusion, this meta-analysis of >125,000 patients suggests that the rate of drug discontinuation and myopathy does not significantly differ between statin- and placebo-treated patients in randomized controlled trials. These findings are limited by the heterogeneity of results, the variable duration of follow-up, and the lower doses of statins compared with contemporary clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13638-0 · Cited by 919
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522 · cited 1×
“Statin intolerance is a common phenomenon and is reported in 5% to 20% of patients, often resulting in drug discontinuation.(1) Stopping statin therapy has been associated with worsened outcomes in patients with cardiovascular diseases (CVDs).”
Background
Cited by
Penson, P. E., Mancini, G. B. J., Toth, P. P., Martin, S. S., Watts, G. F., Sahebkar, A., Mikhailidis, D. P., Banach, M., & on behalf of Lipid and Blood Pressure Meta‐Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP) (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12344 · Cited by 110
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.072 · Cited by 75
Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care
Wiggins, B. S., Backes, J. M., & Hilleman, D. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2681 · Cited by 17
Metadata
- Authors
- Riaz, H., Khan, A. R., Khan, M. S., Rehman, K. A., Alansari, S. A. R., Gheyath, B., Raza, S., Barakat, A., Luni, F. K., Ahmed, H., & Krasuski, R. A.
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 120
- Issue
- 5
- Pages
- 774-781
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2624688719
- Cited by
- 50
- References
- 10
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. https://app.cochat.ai/papers/10.1016/j.amjcard.2017.05.046
- The paper
- Riaz, H., Khan, A. R., Khan, M. S., Rehman, K. A., Alansari, S. A. R., Gheyath, B., Raza, S., Barakat, A., Luni, F. K., Ahmed, H., & Krasuski, R. A. (2017). Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2017.05.046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.